We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Buy CSL Limited (CSLLY) Stock?
Read MoreHide Full Article
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is CSL Limited (CSLLY - Free Report) . CSLLY is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock is trading with P/E ratio of 17.52 right now. For comparison, its industry sports an average P/E of 35.25. Over the last 12 months, CSLLY's Forward P/E has been as high as 28.34 and as low as 17.52, with a median of 21.54.
Investors will also notice that CSLLY has a PEG ratio of 1.46. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CSLLY's industry currently sports an average PEG of 1.75. Over the past 52 weeks, CSLLY's PEG has been as high as 1.94 and as low as 1.29, with a median of 1.62.
Another notable valuation metric for CSLLY is its P/B ratio of 2.96. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. CSLLY's current P/B looks attractive when compared to its industry's average P/B of 3.49. Over the past year, CSLLY's P/B has been as high as 5.05 and as low as 2.96, with a median of 3.87.
Another great Medical - Biomedical and Genetics stock you could consider is Harmony Biosciences (HRMY - Free Report) , which is a Zacks Rank of #2 (Buy) stock with a Value Score of A.
Shares of Harmony Biosciences are currently trading at a forward earnings multiple of 8.82 and a PEG ratio of 0.33 compared to its industry's P/E and PEG ratios of 35.25 and 1.75, respectively.
HRMY's price-to-earnings ratio has been as high as 14.39 and as low as 8.35, with a median of 10.31, while its PEG ratio has been as high as 0.62 and as low as 0.32, with a median of 0.48, all within the past year.
Additionally, Harmony Biosciences has a P/B ratio of 2.42 while its industry's price-to-book ratio sits at 3.49. For HRMY, this valuation metric has been as high as 4.20, as low as 2.23, with a median of 2.87 over the past year.
Value investors will likely look at more than just these metrics, but the above data helps show that CSL Limited and Harmony Biosciences are likely undervalued currently. And when considering the strength of its earnings outlook, CSLLY and HRMY sticks out as one of the market's strongest value stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Should Value Investors Buy CSL Limited (CSLLY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is CSL Limited (CSLLY - Free Report) . CSLLY is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock is trading with P/E ratio of 17.52 right now. For comparison, its industry sports an average P/E of 35.25. Over the last 12 months, CSLLY's Forward P/E has been as high as 28.34 and as low as 17.52, with a median of 21.54.
Investors will also notice that CSLLY has a PEG ratio of 1.46. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CSLLY's industry currently sports an average PEG of 1.75. Over the past 52 weeks, CSLLY's PEG has been as high as 1.94 and as low as 1.29, with a median of 1.62.
Another notable valuation metric for CSLLY is its P/B ratio of 2.96. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. CSLLY's current P/B looks attractive when compared to its industry's average P/B of 3.49. Over the past year, CSLLY's P/B has been as high as 5.05 and as low as 2.96, with a median of 3.87.
Another great Medical - Biomedical and Genetics stock you could consider is Harmony Biosciences (HRMY - Free Report) , which is a Zacks Rank of #2 (Buy) stock with a Value Score of A.
Shares of Harmony Biosciences are currently trading at a forward earnings multiple of 8.82 and a PEG ratio of 0.33 compared to its industry's P/E and PEG ratios of 35.25 and 1.75, respectively.
HRMY's price-to-earnings ratio has been as high as 14.39 and as low as 8.35, with a median of 10.31, while its PEG ratio has been as high as 0.62 and as low as 0.32, with a median of 0.48, all within the past year.
Additionally, Harmony Biosciences has a P/B ratio of 2.42 while its industry's price-to-book ratio sits at 3.49. For HRMY, this valuation metric has been as high as 4.20, as low as 2.23, with a median of 2.87 over the past year.
Value investors will likely look at more than just these metrics, but the above data helps show that CSL Limited and Harmony Biosciences are likely undervalued currently. And when considering the strength of its earnings outlook, CSLLY and HRMY sticks out as one of the market's strongest value stocks.